These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Editorial: targeted therapy for glioblastoma multiforme. Halatsch ME Anticancer Agents Med Chem; 2011 Oct; 11(8):692. PubMed ID: 21864239 [No Abstract] [Full Text] [Related]
24. Predicting Glioblastoma Recurrence by Early Changes in the Apparent Diffusion Coefficient Value and Signal Intensity on FLAIR Images. Chang PD; Chow DS; Yang PH; Filippi CG; Lignelli A AJR Am J Roentgenol; 2017 Jan; 208(1):57-65. PubMed ID: 27726412 [TBL] [Abstract][Full Text] [Related]
26. In-silico oncology: an approximate model of brain tumor mass effect based on directly manipulated free form deformation. Becker S; Mang A; Toma A; Buzug TM Int J Comput Assist Radiol Surg; 2010 Nov; 5(6):607-22. PubMed ID: 20852951 [TBL] [Abstract][Full Text] [Related]
27. Computational quantitative MR image features - a potential useful tool in differentiating glioblastoma from solitary brain metastasis. Petrujkić K; Milošević N; Rajković N; Stanisavljević D; Gavrilović S; Dželebdžić D; Ilić R; Di Ieva A; Maksimović R Eur J Radiol; 2019 Oct; 119():108634. PubMed ID: 31473463 [TBL] [Abstract][Full Text] [Related]
28. Effective treatment of glioblastoma requires crossing the blood-brain barrier and targeting tumors including cancer stem cells: The promise of nanomedicine. Kim SS; Harford JB; Pirollo KF; Chang EH Biochem Biophys Res Commun; 2015 Dec; 468(3):485-9. PubMed ID: 26116770 [TBL] [Abstract][Full Text] [Related]
29. Nonenhancing peritumoral hyperintense lesion on diffusion-weighted imaging in glioblastoma: a novel diagnostic and specific prognostic indicator. Kolakshyapati M; Adhikari RB; Karlowee V; Takayasu T; Nosaka R; Amatya VJ; Takeshima Y; Akiyama Y; Sugiyama K; Kurisu K; Yamasaki F J Neurosurg; 2018 Mar; 128(3):667-678. PubMed ID: 28362236 [TBL] [Abstract][Full Text] [Related]
30. Use of nanoparticles for drug delivery in glioblastoma multiforme. Jain KK Expert Rev Neurother; 2007 Apr; 7(4):363-72. PubMed ID: 17425491 [TBL] [Abstract][Full Text] [Related]
31. Quantitative Clinical Imaging Methods for Monitoring Intratumoral Evolution. Kim JY; Gatenby RA Methods Mol Biol; 2017; 1513():61-81. PubMed ID: 27807831 [TBL] [Abstract][Full Text] [Related]
32. FCNN-based axon segmentation for convection-enhanced delivery optimization. Vidotto M; De Momi E; Gazzara M; Mattos LS; Ferrigno G; Moccia S Int J Comput Assist Radiol Surg; 2019 Mar; 14(3):493-499. PubMed ID: 30613910 [TBL] [Abstract][Full Text] [Related]
33. Focused ultrasound and interleukin-4 receptor-targeted liposomal doxorubicin for enhanced targeted drug delivery and antitumor effect in glioblastoma multiforme. Yang FY; Wong TT; Teng MC; Liu RS; Lu M; Liang HF; Wei MC J Control Release; 2012 Jun; 160(3):652-8. PubMed ID: 22405901 [TBL] [Abstract][Full Text] [Related]
39. Widespread extracranial metastases of glioblastoma multiforme. Report of case and clinicopathological review of cases in literature. Komatsu K; Hiratsuka H; Takahashi S; Kamisasa A; Inaba Y Bull Tokyo Med Dent Univ; 1972 Mar; 19(1):29-49. PubMed ID: 4338365 [No Abstract] [Full Text] [Related]
40. Radiomic Analysis Reveals Prognostic Information in T1-Weighted Baseline Magnetic Resonance Imaging in Patients With Glioblastoma. Ingrisch M; Schneider MJ; Nörenberg D; Negrao de Figueiredo G; Maier-Hein K; Suchorska B; Schüller U; Albert N; Brückmann H; Reiser M; Tonn JC; Ertl-Wagner B Invest Radiol; 2017 Jun; 52(6):360-366. PubMed ID: 28079702 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]